New 'killer engager' drug aims to unleash immune cells on stubborn tumors
NCT ID NCT07541573
First seen Apr 25, 2026 · Last updated May 13, 2026 · Updated 4 times
Summary
This early-phase study tests a new drug called GTB-5550 in adults with advanced solid tumors that have not responded to prior treatments. The drug is designed to bridge natural killer cells to cancer cells, helping the immune system attack the tumor. The main goal is to find the safest dose and see if it can control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Masonic Cancer Center at University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact
Conditions
Explore the condition pages connected to this study.